AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress

RNAi therapeutics made clinical headway in Alzheimer’s disease Monday, as Alnylam announced data from a Phase I study of ALN-APP showing the therapy reduced levels of an Alzheimer’s-linked protein by around two-thirds.